Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial

被引：0
|
作者：
Smolen, Josef [1 ]
Mikuls, Ted [2 ]
Galloway, James [3 ]
Muller-Ladner, Ulf [4 ]
Curtis, Jeffrey [5 ]
Hashimoto, Motomu [6 ]
Takeuchi, Tsutomu [7 ]
Choy, Ernest [8 ]
Tanaka, Yoshiya [9 ]
Cara, Carlos [10 ]
Lauwerys, Bernard [11 ]
Tilt, Nicola [12 ]
Ufuktepe, Baran [13 ]
Taylor, Peter C. [14 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Univ Nebraska Med Ctr, Omaha, NE USA
[3] Kings Coll London, Ctr Rheumat Dis, London, England
[4] Justus Liebig Univ Giessen, Bad Nauheim, Germany
[5] Univ Alabama Birmingham, Hoover, AL USA
[6] Osaka Metropolitan Univ, Osaka, Japan
[7] Keio Univ, Dept Internal Med, Tokyo, Japan
[8] Cardiff Univ Sch Med, Cardiff, Wales
[9] Univ Occupat & Environm Hlth, Dept Internal Med, Kitakyushu, Fukuoka, Japan
[10] UCB Pharma, Madrid, Spain
[11] UCB Pharma, Brussels, Belgium
[12] UCB Pharma, Slough, Berks, England
[13] UCB Pharma, Istanbul, Turkiye
[14] Univ Oxford, Oxford, England
来源：
ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0511
引用
收藏
页码：1036 / 1039
页数：4
相关论文
共 50 条
  • [21] Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial
    Smolen, Josef S.
    Taylor, Peter C.
    Tanaka, Yoshiya
    Cara, Carlos
    Lauwerys, Bernard
    Xavier, Ricardo
    Curtis, Jeffrey R.
    Mikuls, Ted R.
    Weinblatt, Michael
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4240 - 4243
  • [22] Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
    Smolen, Josef
    Burmester, Gerd
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Curtis, Jeffrey
    Mikuls, Ted
    Lopez Medina, Clementina
    Taylor, Peter C.
    Tilt, Nicola
    Lauwerys, Bernard
    Ufuktepe, Baran
    Huizinga, Thomas
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4597 - 4600
  • [23] Responsiveness of different dynamic contrast-enhanced magnetic resonance imaging approaches: a post-hoc analysis of a randomized controlled trial of certolizumab pegol in rheumatoid arthritis
    Axelsen, M. B.
    Boesen, M.
    Bliddal, H.
    Jacobsson, L. T. H.
    Hansen, M. S.
    Ostergaard, M.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2020, 49 (02) : 105 - 111
  • [24] Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial
    Keystone, Edward C.
    Curtis, Jeffrey R.
    Fleischmann, Roy M.
    Furst, Daniel E.
    Khanna, Dinesh
    Smolen, Josef S.
    Mease, Philip J.
    Schiff, Michael H.
    Coteur, Geoffroy
    Davies, Owen
    Combe, Bernard
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (06) : 990 - 996
  • [25] TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND CO-OCCURRENCE OF DEPRESSION AND/OR ANXIETY: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 CLINICAL TRIALS
    Citera, Gustavo
    Jain, Rakesh
    Irazoque, Fedra
    Guzman, Renato
    Madariaga, Hugo
    Gruben, David
    Wang, Lisy
    Stockert, Lori
    Hsu, Ming-Ann
    Santana, Karina
    Ebrahim, Abbas
    Ponce de Leon, Dario
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 6 - 6
  • [26] A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol
    Curtis, Jeffrey R.
    Churchill, Melvin
    Kivitz, Alan
    Samad, Ahmed
    Gauer, Laura
    Gervitz, Leon
    Koetse, Willem
    Melin, Jeffrey
    Yazici, Yusuf
    ARTHRITIS & RHEUMATOLOGY, 2015, 67 (12) : 3104 - 3112
  • [27] BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL IN THE MANAGEMENT OF PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS IN GREECE
    Tzanetakos, C.
    Maniadakis, N.
    Kourlaba, G.
    Tzioufas, A.
    Goules, A.
    Theodoratou, T.
    Christou, P.
    VALUE IN HEALTH, 2014, 17 (07) : 375 - 375
  • [28] ANALYSIS OF THE ASSOCIATION BETWEEN CIGARETTE SMOKING AND CLINICAL RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT IN HUNGARIAN PATIENTS WITH RHEUMATOID ARTHRITIS
    Szekanecz, Z.
    Pulai, J.
    Drescher, E.
    Varga, T.
    Kiss, C.
    Gal, J.
    Kerekes, K.
    Orosz, R.
    Dunkel, J.
    Koncz, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 474 - 474
  • [29] CERTOLIZUMAB PEGOL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ALIGNED WITH NICE GUIDANCE FOR ANTI-TNF THERAPY: POST-HOC ANALYSES OF THE REALISTIC PHASE IIIB RANDOMIZED CONTROLLED STUDY
    Weinblatt, M. E.
    Fleischmann, R.
    van Vollenhoven, R.
    Emery, P.
    Huizinga, T. W. J.
    Goldermann, R.
    Duncan, B.
    Timoshanko, J.
    Luijtens, K.
    Davies, O.
    Dougados, M.
    RHEUMATOLOGY, 2012, 51 : 125 - 126
  • [30] Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain - an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial
    Schenker, Hannah
    Hess, Andreas
    Konerth, Laura
    Sergeeva, Marina
    Prade, Jutta
    Kleyer, Arnd
    Reiser, Michaela
    Hueber, Axel J.
    Englbrecht, Matthias
    Feist, Eugen
    Voll, Reinhard
    Bannert, Bettina
    Baerwald, C.
    Roesch, Julie
    Doerfler, Arnd
    da Silva, Jose Antonio P.
    Damjanov, Nemanja
    Schett, Georg
    Rech, Juergen
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345